USFDA taps Zydus, Cipla to ease drug shortage

USFDA taps Zydus, Cipla to ease drug shortage. The USFDA has identified Zydus Lifesciences and Cipla as key suppliers to address the ifosfamide shortage in the US market. This presents a near-term export opportunity for both companies amid rising global demand. Regulatory approvals from USFDA could boost volumes and margins.
📊 STOCKS: ZYDUSLIFE, CIPLA | 🏢 SECTOR: Pharma | #MEDIUMIMPACT #Pharma